{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T03:54:50Z","timestamp":1793418890434,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2025A1515010366"],"award-info":[{"award-number":["2025A1515010366"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515010449"],"award-info":[{"award-number":["2023A1515010449"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016870","name":"CSC Global Foundation","doi-asserted-by":"publisher","award":["202006250036 (J.W.)"],"award-info":[{"award-number":["202006250036 (J.W.)"]}],"id":[{"id":"10.13039\/100016870","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mesenchymal stem cells (MSCs) have emerged as promising candidates to treat clinical liver fibrosis. However, the key factors and mechanisms underlying their antifibrotic effects remain largely unclear. Our aims were to assess the therapeutic efficacy of human umbilical cord (UC) MSCs in a murine liver fibrosis model, and to dissect the influence of their secretome in vitro.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Liver fibrosis was induced in mice using carbon tetrachloride (CCl\u2084). Fluorescent labeling was used to track UC-MSC distribution post-injection, comparing intraperitoneal (IP) and intravenous (IV) delivery. UC-MSCs were administered intraperitoneally weekly, starting at either fibrosis induction (prevention) or after six weeks (therapeutic). Fibrosis severity was evaluated by hematoxylin and eosin (H&amp;E) staining, Masson\u2019s trichrome staining and immunohistochemical (IHC) staining for alpha smooth muscle actin (\u03b1-SMA). Human hepatic stellate LX-2 cells were treated with complete UC-MSC-conditioned medium (CM\n                      <jats:sup>UC\u2212MSC<\/jats:sup>\n                      ), its soluble factors (SF\n                      <jats:sup>UC\u2212MSC<\/jats:sup>\n                      ) or extracellular vesicle fraction of the secretome (EV\n                      <jats:sup>UC\u2212MSC<\/jats:sup>\n                      ). Fibrosis-related gene and protein expression were analyzed by Q-PCR, immunofluorescence, and Western blotting.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      IP-injected UC-MSCs showed increased liver-specific accumulation compared to IV-injected UC-MSC that distributed mostly to the lungs. In vivo, IP-injected UC-MSC significantly reduced fibrosis, as evidenced by decreased histological damage, collagen deposition, and \u03b1-SMA expression. Both preventive and therapeutic UC-MSC IP-treatments were effective. In vitro, CM\n                      <jats:sup>UC\u2212MSC<\/jats:sup>\n                      suppressed TGF-\u03b2-induced\n                      <jats:italic>ACTA2<\/jats:italic>\n                      \/\u03b1-SMA expression and proliferation of human LX-2 cells, but not\n                      <jats:italic>COL1A1<\/jats:italic>\n                      \/collagen type I expression. These effects persisted in EV-depleted SF\n                      <jats:sup>UC\u2212MSC<\/jats:sup>\n                      . EV\n                      <jats:sup>UC\u2212MSC<\/jats:sup>\n                      inhibited proliferation, but did not suppress\n                      <jats:italic>ACTA2<\/jats:italic>\n                      \/\u03b1-SMA or\n                      <jats:italic>COL1A1<\/jats:italic>\n                      \/collagen type I levels in LX-2 cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IP-administered therapeutic UC-MSCs preferentially accumulate in the liver and effectively prevent and reverse liver fibrosis in mice, while inhibiting hepatic stellate cell activation in vitro. The antifibrotic effects in vivo are likely primarily mediated by excreted soluble factors rather than extracellular vesicles.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13287-025-04812-6","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T15:13:38Z","timestamp":1764256418000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Human umbilical cord mesenchymal stem cells attenuate liver fibrosis in mice and inhibit hepatic stellate cell activation by secreting soluble factors"],"prefix":"10.1186","volume":"16","author":[{"given":"Qi","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruyi","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janette","family":"Heegsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Moshage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin C.","family":"Harmsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaas Nico","family":"Faber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3325-8062","authenticated-orcid":false,"given":"Pingnan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"issue":"3","key":"4812_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","volume":"18","author":"T Kisseleva","year":"2021","unstructured":"Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 2021;18(3):151\u201366.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"9","key":"4812_CR2","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.tips.2020.06.009","volume":"41","author":"N Song","year":"2020","unstructured":"Song N, Scholtemeijer M, Shah K. Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential. Trends Pharmacol Sci. 2020;41(9):653\u201364.","journal-title":"Trends Pharmacol Sci"},{"key":"4812_CR3","doi-asserted-by":"crossref","unstructured":"Wang H, Yao W, Wang Y, Dong H, Dong T, Zhou W et al. Meta-analysis on last ten years of clinical injection of bone marrow-derived and umbilical cord MSC to reverse cirrhosis or rescue patients with acute-on-chronic liver failure. Stem Cell Res Ther. 2023;14(1).","DOI":"10.1186\/s13287-023-03494-2"},{"key":"4812_CR4","doi-asserted-by":"crossref","unstructured":"Lotfy A, AboQuella NM, Wang H. Mesenchymal stromal\/stem cell (MSC)-derived exosomes in clinical trials. Stem Cell Res Ther. 2023;14(1).","DOI":"10.1186\/s13287-023-03287-7"},{"issue":"1","key":"4812_CR5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1186\/s13287-020-02011-z","volume":"11","author":"Q Xie","year":"2020","unstructured":"Xie Q, Liu R, Jiang J, Peng J, Yang C, Zhang W, et al. What is the impact of human umbilical cord mesenchymal stem cell transplantation on clinical treatment? Stem Cell Res Ther. 2020;11(1):519.","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"4812_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy. 2006;8(4):315\u20137.","journal-title":"Cytotherapy"},{"issue":"1","key":"4812_CR7","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1186\/s13287-022-03010-y","volume":"13","author":"S Tian","year":"2022","unstructured":"Tian S, Zhou X, Zhang M, Cui L, Li B, Liu Y, et al. Mesenchymal stem cell-derived exosomes protect against liver fibrosis via delivering miR-148a to target KLF6\/STAT3 pathway in macrophages. Stem Cell Res Ther. 2022;13(1):330.","journal-title":"Stem Cell Res Ther"},{"key":"4812_CR8","doi-asserted-by":"publisher","first-page":"113895","DOI":"10.1016\/j.expneurol.2021.113895","volume":"347","author":"J Zhang","year":"2022","unstructured":"Zhang J, Buller BA, Zhang ZG, Zhang Y, Lu M, Rosene DL, et al. Exosomes derived from bone marrow mesenchymal stromal cells promote remyelination and reduce neuroinflammation in the demyelinating central nervous system. Exp Neurol. 2022;347:113895.","journal-title":"Exp Neurol"},{"issue":"1","key":"4812_CR9","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s13287-022-02882-4","volume":"13","author":"Y Liu","year":"2022","unstructured":"Liu Y, Dong Y, Wu X, Xu X, Niu J. The assessment of mesenchymal stem cells therapy in acute on chronic liver failure and chronic liver disease: a systematic review and meta-analysis of randomized controlled clinical trials. Stem Cell Res Ther. 2022;13(1):204.","journal-title":"Stem Cell Res Ther"},{"key":"4812_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13287-015-0271-2","volume":"7","author":"J Leibacher","year":"2016","unstructured":"Leibacher J, Henschler R. Biodistribution, migration and homing of systemically applied mesenchymal stem\/stromal cells. Stem Cell Res Ther. 2016;7:7.","journal-title":"Stem Cell Res Ther"},{"key":"4812_CR11","doi-asserted-by":"publisher","first-page":"6685605","DOI":"10.1155\/2021\/6685605","volume":"2021","author":"Q Zhou","year":"2021","unstructured":"Zhou Q, Gu T, Zhang Y, Li H, Zhuansun X, Xu S, et al. Human umbilical cord mesenchymal stem cells ameliorate hepatic stellate cell activation and liver fibrosis by upregulating MicroRNA-455-3p through suppression of p21-Activated Kinase-2. Biomed Res Int. 2021;2021:6685605.","journal-title":"Biomed Res Int"},{"issue":"4","key":"4812_CR12","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1002\/hep.26135","volume":"57","author":"CK Huang","year":"2013","unstructured":"Huang CK, Lee SO, Lai KP, Ma WL, Lin TH, Tsai MY, et al. Targeting androgen receptor in bone marrow mesenchymal stem cells leads to better transplantation therapy efficacy in liver cirrhosis. Hepatology. 2013;57(4):1550\u201363.","journal-title":"Hepatology"},{"issue":"2","key":"4812_CR13","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.stem.2017.07.011","volume":"21","author":"E El Agha","year":"2017","unstructured":"El Agha E, Kramann R, Schneider RK, Li X, Seeger W, Humphreys BD, et al. Mesenchymal stem cells in fibrotic disease. Cell Stem Cell. 2017;21(2):166\u201377.","journal-title":"Cell Stem Cell"},{"issue":"47","key":"4812_CR14","doi-asserted-by":"publisher","first-page":"7444","DOI":"10.3748\/wjg.v26.i47.7444","volume":"26","author":"Z Al-Dhamin","year":"2020","unstructured":"Al-Dhamin Z, Liu LD, Li DD, Zhang SY, Dong SM, Nan YM. Therapeutic efficiency of bone marrow-derived mesenchymal stem cells for liver fibrosis: A systematic review of in vivo studies. World J Gastroenterol. 2020;26(47):7444\u201369.","journal-title":"World J Gastroenterol"},{"key":"4812_CR15","doi-asserted-by":"crossref","unstructured":"Nazarie Ignat SR, Gharbia S, Hermenean A, Dinescu S, Costache M. Regenerative Potential of Mesenchymal Stem Cells\u2019 (MSCs) Secretome for Liver Fibrosis Therapies. Int J Mol Sci. 2021;22(24).","DOI":"10.3390\/ijms222413292"},{"key":"4812_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/adfm.201909125","volume":"30","author":"M\u00c1 Brennan","year":"2020","unstructured":"Brennan M\u00c1, Layrolle P, Mooney DJ. Biomaterials functionalized with MSC secreted extracellular vesicles and soluble factors for tissue regeneration. Adv Funct Mater. 2020;30:37.","journal-title":"Adv Funct Mater"},{"issue":"6","key":"4812_CR17","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1136\/gutjnl-2011-300908","volume":"61","author":"DS Zagoura","year":"2012","unstructured":"Zagoura DS, Roubelakis MG, Bitsika V, Trohatou O, Pappa KI, Kapelouzou A, et al. Therapeutic potential of a distinct population of human amniotic fluid mesenchymal stem cells and their secreted molecules in mice with acute hepatic failure. Gut. 2012;61(6):894\u2013906.","journal-title":"Gut"},{"key":"4812_CR18","doi-asserted-by":"crossref","unstructured":"Lin Y, Yan M, Bai Z, Xie Y, Ren L, Wei J et al. Huc-MSC-derived exosomes modified with the targeting peptide of aHSCs for liver fibrosis therapy. J Nanobiotechnol. 2022;20(1).","DOI":"10.1186\/s12951-022-01636-x"},{"key":"4812_CR19","doi-asserted-by":"publisher","first-page":"106139","DOI":"10.1016\/j.phrs.2022.106139","volume":"178","author":"G Tong","year":"2022","unstructured":"Tong G, Chen X, Lee J, Fan J, Li S, Zhu K, et al. Fibroblast growth factor 18 attenuates liver fibrosis and HSCs activation via the SMO-LATS1-YAP pathway. Pharmacol Res. 2022;178:106139.","journal-title":"Pharmacol Res"},{"issue":"1","key":"4812_CR20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1186\/s13287-020-01895-1","volume":"11","author":"C Hu","year":"2020","unstructured":"Hu C, Zhao L, Zhang L, Bao Q, Li L. Mesenchymal stem cell-based cell-free strategies: safe and effective treatments for liver injury. Stem Cell Res Ther. 2020;11(1):377.","journal-title":"Stem Cell Res Ther"},{"key":"4812_CR21","doi-asserted-by":"publisher","first-page":"820685","DOI":"10.3389\/fimmu.2022.820685","volume":"13","author":"L Wang","year":"2022","unstructured":"Wang L, Deng Z, Sun Y, Zhao Y, Li Y, Yang M, et al. The study on the regulation of Th cells by mesenchymal stem cells through the JAK-STAT signaling pathway to protect naturally aged sepsis model rats. Front Immunol. 2022;13:820685.","journal-title":"Front Immunol"},{"key":"4812_CR22","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/978-1-0716-1382-5_23","volume":"2299","author":"A Ravichandra","year":"2021","unstructured":"Ravichandra A, Schwabe RF. Mouse models of liver fibrosis. Methods Mol Biol. 2021;2299:339\u201356.","journal-title":"Methods Mol Biol"},{"issue":"3","key":"4812_CR23","doi-asserted-by":"publisher","first-page":"167020","DOI":"10.1016\/j.bbadis.2024.167020","volume":"1870","author":"J Wang","year":"2024","unstructured":"Wang J, Wu Z, Xia M, Salas SS, Ospina JA, Buist-Homan M, et al. Extracellular vesicles derived from liver sinusoidal endothelial cells inhibit the activation of hepatic stellate cells and Kupffer cells in vitro. Biochim Biophys Acta Mol Basis Dis. 2024;1870(3):167020.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"13","key":"4812_CR24","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.7150\/thno.70448","volume":"12","author":"D Hao","year":"2022","unstructured":"Hao D, Lu L, Song H, Duan Y, Chen J, Carney R, et al. Engineered extracellular vesicles with high collagen-binding affinity present superior in situ retention and therapeutic efficacy in tissue repair. Theranostics. 2022;12(13):6021\u201337.","journal-title":"Theranostics"},{"issue":"2","key":"4812_CR25","doi-asserted-by":"publisher","first-page":"e21219","DOI":"10.1096\/fj.202001564RR","volume":"35","author":"N Smith-Cortinez","year":"2021","unstructured":"Smith-Cortinez N, Fagundes RR, Gomez V, Kong D, de Waart DR, Heegsma J, et al. Collagen release by human hepatic stellate cells requires vitamin C and is efficiently blocked by hydroxylase Inhibition. FASEB J. 2021;35(2):e21219.","journal-title":"FASEB J"},{"issue":"1","key":"4812_CR26","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1136\/gut.2004.042127","volume":"54","author":"L Xu","year":"2005","unstructured":"Xu L, Hui AY, Albanis E, Arthur MJ, O\u2019Byrne SM, Blaner WS, et al. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut. 2005;54(1):142\u201351.","journal-title":"Gut"},{"issue":"1","key":"4812_CR27","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s13287-023-03493-3","volume":"14","author":"D Kong","year":"2023","unstructured":"Kong D, Mourtzinos A, Heegsma J, Blokzijl H, de Meijer VE, Faber KN. Growth differentiation factor 7 autocrine signaling promotes hepatic progenitor cell expansion in liver fibrosis. Stem Cell Res Ther. 2023;14(1):288.","journal-title":"Stem Cell Res Ther"},{"issue":"3","key":"4812_CR28","doi-asserted-by":"publisher","first-page":"165621","DOI":"10.1016\/j.bbadis.2019.165621","volume":"1866","author":"Y Geng","year":"2020","unstructured":"Geng Y, Hernandez Villanueva A, Oun A, Buist-Homan M, Blokzijl H, Faber KN, et al. Protective effect of Metformin against palmitate-induced hepatic cell death. Biochim Biophys Acta Mol Basis Dis. 2020;1866(3):165621.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"1","key":"4812_CR29","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s13287-022-02858-4","volume":"13","author":"M Yuan","year":"2022","unstructured":"Yuan M, Hu X, Yao L, Jiang Y, Li L. Mesenchymal stem cell homing to improve therapeutic efficacy in liver disease. Stem Cell Res Ther. 2022;13(1):179.","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"4812_CR30","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/stem.2549","volume":"35","author":"G Pachon-Pena","year":"2017","unstructured":"Pachon-Pena G, Donnelly C, Ruiz-Canada C, Katz A, Fernandez-Veledo S, Vendrell J, et al. A glycovariant of human CD44 is characteristically expressed on human mesenchymal stem cells. Stem Cells. 2017;35(4):1080\u201392.","journal-title":"Stem Cells"},{"key":"4812_CR31","doi-asserted-by":"publisher","first-page":"8906945","DOI":"10.1155\/2016\/8906945","volume":"2016","author":"K Xiao Ling","year":"2016","unstructured":"Xiao Ling K, Peng L, Jian Feng Z, Wei C, Wei Yan Y, Nan S, et al. Stromal derived Factor-1\/CXCR4 axis involved in bone marrow mesenchymal stem cells recruitment to injured liver. Stem Cells Int. 2016;2016:8906945.","journal-title":"Stem Cells Int"},{"issue":"2","key":"4812_CR32","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s00774-020-01122-0","volume":"39","author":"H Zhang","year":"2021","unstructured":"Zhang H, Li X, Li J, Zhong L, Chen X, Chen S. SDF-1 mediates mesenchymal stem cell recruitment and migration via the SDF-1\/CXCR4 axis in bone defect. J Bone Min Metab. 2021;39(2):126\u201338.","journal-title":"J Bone Min Metab"},{"issue":"3","key":"4812_CR33","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.jhep.2014.10.030","volume":"62","author":"RP Meier","year":"2015","unstructured":"Meier RP, Mahou R, Morel P, Meyer J, Montanari E, Muller YD, et al. Microencapsulated human mesenchymal stem cells decrease liver fibrosis in mice. J Hepatol. 2015;62(3):634\u201341.","journal-title":"J Hepatol"},{"issue":"12","key":"4812_CR34","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1096\/fj.201600433R","volume":"30","author":"D Haldar","year":"2016","unstructured":"Haldar D, Henderson NC, Hirschfield G, Newsome PN. Mesenchymal stromal cells and liver fibrosis: a complicated relationship. FASEB J. 2016;30(12):3905\u201328.","journal-title":"FASEB J"},{"issue":"3","key":"4812_CR35","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/sctm.18-0105","volume":"8","author":"Y Watanabe","year":"2019","unstructured":"Watanabe Y, Tsuchiya A, Seino S, Kawata Y, Kojima Y, Ikarashi S, et al. Mesenchymal stem cells and induced bone Marrow-Derived macrophages synergistically improve liver fibrosis in mice. Stem Cells Transl Med. 2019;8(3):271\u201384.","journal-title":"Stem Cells Transl Med"},{"issue":"1","key":"4812_CR36","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13287-018-1122-8","volume":"10","author":"XY Luo","year":"2019","unstructured":"Luo XY, Meng XJ, Cao DC, Wang W, Zhou K, Li L, et al. Transplantation of bone marrow mesenchymal stromal cells attenuates liver fibrosis in mice by regulating macrophage subtypes. Stem Cell Res Ther. 2019;10(1):16.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"4812_CR37","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12951-023-01942-y","volume":"21","author":"F Cheng","year":"2023","unstructured":"Cheng F, Yang F, Wang Y, Zhou J, Qian H, Yan Y. Mesenchymal stem cell-derived Exosomal miR-27b-3p alleviates liver fibrosis via downregulating YAP\/LOXL2 pathway. J Nanobiotechnol. 2023;21(1):195.","journal-title":"J Nanobiotechnol"},{"issue":"4","key":"4812_CR38","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1097\/HEP.0000000000000831","volume":"81","author":"X Feng","year":"2025","unstructured":"Feng X, Feng B, Zhou J, Yang J, Pan Q, Yu J, et al. Mesenchymal stem cells alleviate mouse liver fibrosis by inhibiting pathogenic function of intrahepatic B cells. Hepatology. 2025;81(4):1211\u201327.","journal-title":"Hepatology"},{"key":"4812_CR39","doi-asserted-by":"crossref","unstructured":"Usunier B, Brossard C, L\u2019Homme B, Linard C, Benderitter M, Milliat F et al. HGF and TSG-6 released by mesenchymal stem cells attenuate colon Radiation-Induced fibrosis. Int J Mol Sci. 2021;22(4).","DOI":"10.3390\/ijms22041790"},{"issue":"1","key":"4812_CR40","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11307-015-0869-x","volume":"18","author":"L Lai","year":"2016","unstructured":"Lai L, Chen J, Wei X, Huang M, Hu X, Yang R, et al. Transplantation of MSCs overexpressing HGF into a rat model of liver fibrosis. Mol Imaging Biol. 2016;18(1):43\u201351.","journal-title":"Mol Imaging Biol"},{"issue":"18","key":"4812_CR41","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1163\/156856211X614761","volume":"23","author":"H Ishikawa","year":"2012","unstructured":"Ishikawa H, Jo J, Tabata Y. Liver Anti-Fibrosis therapy with mesenchymal stem cells secreting hepatocyte growth factor. J Biomater Sci Polym Ed. 2012;23(18):2259\u201372.","journal-title":"J Biomater Sci Polym Ed"},{"key":"4812_CR42","doi-asserted-by":"crossref","unstructured":"AbdRabou M, Massoud D, Mehany A, Alghamdi F, Alrayes Z, Asran A et al. Comparative therapeutic efficacy of Olea Europaea L. leaf extract and bone marrow-derived mesenchymal stem cells in ameliorating streptozotocin-induced hepatic and Splenic damage in pregnant rats: mechanisms of antioxidant and anti-apoptotic protection. Plant Sci Today. 2025.","DOI":"10.14719\/pst.6955"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-025-04812-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-025-04812-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-025-04812-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T04:19:09Z","timestamp":1767068349000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13287-025-04812-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4812"],"URL":"https:\/\/doi.org\/10.1186\/s13287-025-04812-6","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"21 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For UC-MSC experiments: (1) Title of the approved project: Histone phosphorylation-mediated mechanisms by which human umbilical cord mesenchymal stem cells alleviate sepsis-induced lung injury; (2) Name of the institutional approval committee or unit: The Ethics Committee of the Second Affiliated Hospital of Shantou University Medical College; (3) Approval number: No.2021-89; (4) Date of approval: 2021\/07\/26. For animal experiments: (1) Title of the approved project: A mechanistic investigation into the therapeutic potential of selectively regulating MMP2 and other pro-Angiogenic factors secreted by mesenchymal stem cells in liver fibrosis; (2) Name of the institutional approval committee or unit: The Experimental Animal Ethics Committee of Shantou University Medical College; (3) Approval number: SUMCXM2024-262; (4) Date of approval: 2024\/07\/12.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agreed on the final approval of the version to be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors of this manuscript have no conflicts of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"698"}}